Humanized antibodies to ganglioside GM.sub.2

Details Humanized antibodies to ganglioside GM.sub.2 Humanized antibodies to ganglioside GM.sub.2

1996-06-27

2000-03-28

Caputa, Anthony C.

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

4241371, 4241411, 435 696, 435 7021, 4351722, 4353201, 435326, 435328, 435329, 5303873, 5303875, 530867, 536 2353, A61K 39395, A61K 3940, C12P 2104, C12P 2108

Patent

active

060428287

ABSTRACT:
Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

REFERENCES:
patent: 5585089 (1996-12-01), Queen et al.
Harris (Tibtech vol. 11, pp. 42-44, 1993).
Osband et al. (Immunology Today vol. 111 No. 6, 1990, pp. 193-195).
Oi and Morrison et al. (Biotechniques vol. 4, pp. 214-221) (1986).
Reichmann et al (Nature, vol. 332, pp. 323-227) (1988).
Morrison et al (Advances in Immunology vol. 44 Dixon et al Eds. Academic Press 1989 pp. 65-92).
Schlom et al (Molecular Foundations of Oncology, Broder Ed. Williams & Wilkins, 1991 pp. 95-134).
Hakamori et al (Monoclonal Antibodies & Functional Cell Lines Kenner et al Ed. 1985 pp. 67-100).
Kannagi et al (Handbook of Experimental Immunology vol. 4 1986 pp. 117.1-117.4).
Irie et al (Lancet Apr. 8, 1989 pp. 786-787).
Natoli et al (Cancer Research vol. 46, Aug. 1986 pp. 4116-4120).
Fredman et al (J. of Biol. Chem. vol. 21, Jul. 1989 pp. 12122-12125).
Miyaki et al (Cancer Research vol. 48, Nov. 1988 pp. 6154-6160).
Reeck et al (Cell vol. 50, p. 667), Aug. 28, 1987.

Affiliated with

Also associated with

Rating

Humanized antibodies to ganglioside GM.sub.2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Humanized antibodies to ganglioside GM.sub.2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibodies to ganglioside GM.sub.2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1323674